John M. Kalas practices in the Firm's Complex Litigation, Environmental, Pharmaceutical Products, and Toxic Torts & Products Liability groups. His practice is focused on deconstructing the opposition’s core corporate liability and scientific theories. To that end, he has taken and defended dozens of successful depositions of expert and fact witnesses. He has participated in several multi-day Daubert hearings and has significant trial experience as a member of multiple trial teams in jurisdictions nationwide.

Currently, Mr. Kalas is serving as trial counsel in litigation involving co-exposures to agricultural and industrial chemicals that have allegedly led to the development of lymphatic cancer. The first trial in this novel mass tort will take place in 2023, and Mr. Kalas – along with his co-counsel – has worked diligently to expose the contradictions and weaknesses in plaintiffs’ claims. He is also part of the defense team representing an agricultural company in litigation involving claims of cancer from exposure to pesticides, centralized before the United States District Court for the Northern District of California, and in California, Delaware, and Missouri state courts. As part of that litigation, he has led a team focused on developing experts to evaluate exposure and dose issues and on deconstructing the theories of plaintiffs' exposure, dose, and toxicology experts.

In the past, Mr. Kalas litigated personal injury and property damage claims following alleged exposure to perchlorate and other volatile organic compounds from groundwater contamination, and defended wrongful death claims associated with alleged exposure to airborne toxins in international litigation spanning three continents. He has defended birth defect claims allegedly associated with occupational and residential chemical exposure, and has represented employers seeking to enforce choice-of-law and arbitration agreements contained within employees’ employment contracts. He also played a substantial role in the defense of Novartis Pharmaceuticals Corporation in bisphosphonate litigation centralized in Tennessee and New Jersey. He contributed significantly to motions practice in that litigation, researching and drafting scores of successful dispositive and Daubert motions.

Mr. Kalas is a member of the Atlantic Legal Foundation Science Advisory Committee and a member of the Defense Research Institute.


  • Old and New Targets: IARC Releases its 2020-2024 Priority List for Evaluation
  • "Super-Size My Litigation? Perfluorochemicals And Food Packaging"
  • Nestle Takes Shelter in Its Supply Chain Safe Harbor
  • The Road to Denial: An Analysis of the Trends and Bases for Denial of Multidistrict Litigation Requests
  • Issuer Banks and Data Breach Lawsuits: A New Wave of Litigation?
  • High Court's Cert Denial Foments Greater Confusion Over Removal of Mass Actions Under Federal Law